Ratings Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd

Equities

End-of-day quote Shanghai S.E. Other stock markets 23:00:00 04/06/2024 BST			5-day change	1st Jan Change
22.5 ^CNY	-0.53%		-0.49%	-0.04%

04-25	Sunshine Guojian Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-21	Sunshine Guojian Pharmaceutical's Profit Surges Sixfold in 2023	MT

The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 43.27 times its estimated earnings per share for the ongoing year.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The company's earnings releases usually do not meet expectations.

	1st Jan change	Capi.	ESG Refinitiv
SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD	-0.04%	1.93B	-
CSL LIMITED	-0.28%	90.59B	A-
SAMSUNG BIOLOGICS CO.,LTD.	0.00%	38.99B	A-
BIOGEN INC.	-8.80%	34.09B	B-
UCB	+64.13%	26.38B	A
BIOMARIN PHARMACEUTICAL INC.	-18.27%	15.02B	C
INCYTE CORPORATION	-6.20%	13.17B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.69%	11.88B	D+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-47.78%	10.65B	B
SWEDISH ORPHAN BIOVITRUM AB	+8.09%	9.25B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality